FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the stock. StockNews.com lowered shares of FibroGen from a "buy" rating to a "hold" rating in a report on Wednesday. The Goldman Sachs Group cut their price objective on shares of FibroGen from $9.00 to $8.00 and set a "sell" rating on the stock in a report on Tuesday, May 24th.
FibroGen Stock Up 2.5 %
NASDAQ:FGEN opened at $14.47 on Thursday. The firm's fifty day simple moving average is $11.63 and its two-hundred day simple moving average is $12.01. FibroGen has a 12-month low of $7.81 and a 12-month high of $16.91.
FibroGen (NASDAQ:FGEN - Get Rating) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.16. FibroGen had a negative net margin of 83.64% and a negative return on equity of 100.51%. The business had revenue of $29.81 million for the quarter, compared to analyst estimates of $36.15 million. During the same period in the previous year, the company earned ($1.45) earnings per share. The business's revenue for the quarter was up 22.3% on a year-over-year basis. On average, analysts predict that FibroGen will post -3.39 earnings per share for the current fiscal year.